56 results about "PSYCHIC DISORDER" patented technology

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit / hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.

The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.

The invention provides methods for treating epilepsy, mental disorders and / or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and / or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and / or deficits in sensory organ.

The present invention provides the identification of a number of SNPs that are associated schizophrenia, schizoaffective disorder, bipolar disorder and related mental disorders which were found to be strongly linked to individuals with the disease. The invention provides SNP locations on human chromosome 6, as well as methods of making PCR primers and assays for detecting the SNPs in tested individuals.

The invention relates to a drug for treating senile postoperative acute mental disorders. The drug is prepared from the following substances in proportion by weight: common alstonia bark leaves, herba selaginellae, ophicslcite ophicalcitum, fagopyrum cymosum, fiveleaf akebia fruits, euryale ferox, pummelo peel, celosia cristata, stalactite, folium polygoni tnctorii, seeds of Chinese dodder, grand torreya seeds, litchi, dyosma difformis, eucommia ulmoides, exocarpium benincasae, peucedanum decursivum maxim, tuber fleeceflower stems, chingma abutilon seeds, longan pulp, semen lepidii, soybean germinated, biotite schist and mica, valeriana jatamansi jones, saxifraga stolonifera, spina gleditsiae, folium turpiniae, Chinese honey locust, glechoma longituba, nodular branches of pine, adonis, impatiens balsamina, caulis bambusae in taeniam, desert asparagus, murraya paniculata, saururus chinensis, string beans, leaves of purpleflower holly, veronicastrum herb, Chinese starjasmine stems, abalone, lysionotius pauciflorus maxim, radix ampelopsis, radix scrophulariae, microcos paniculata, dayflowers, fructus piperis longi, corn stigmas, huperzia serrata and amethyst. The drug for treating senile postoperative acute mental disorders disclosed by the invention is prepared from natural medicines, has a clear curative effect, can be used for effectively treating the senile postoperative acute mental disorders, and therefore, the drug is very suitable for clinical application.

Mice in which OCT3 expression is suppressed were successfully constructed by administering antisense against OCT3 gene into the brain. Mice in which OCT3 expression is suppressed display phenotypes related to mental disorders such as anti-depression and anti-anxiety, and therefore the mice can be applied to the screening of therapeutic agents for mental disorders. In addition, substances suppressing the OCT3 expression or function were shown to be in fact effective as therapeutic agents for depression and anxiety neuroses.

The invention relates to methods of diagnosing or monitoring a psychotic disorder in a subject comprising providing a test biological sample from the subject, performing spectral analysis on said test biological sample to provide one or more spectra, and, comparing the one or more spectra with one or more control spectra. The invention also relates to methods for diagnosing or monitoring psychotic disorders such as schizophrenic or bipolar disorders, comprising measuring the level of one or more biomarkers present in a biological sample taken from a test subject, said biomarkers being selected from the group consisting of transthyretin, ApoA1, VLDL, LDL and aromatic species such as plasma proteins. The invention also relates to sensors, biosensors, multi-analyte panels, arrays, assays and kits for performing methods of the invention.

The invention relates to a method of differential diagnosis of schizophrenia or other psychotic disorder from a further psychiatric disorder.

Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.

The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia or bipolar disorder. The present invention more particularly discloses the identification of human genes that can be used for the diagnosis, prevention and treatment of schizophrenia, bipolar disorder and related disorders, as well as for the screening of therapeutically active drugs to treat said disorders. The invention further discloses specific polymorphisms or alleles of the KCNQ3 gene that are related to schizophrenia or bipolar disorder, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and / or treatment of schizophrenia, bipolar disorder and related disorders.

The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.

The present invention relates of the mammalian HKNG1 gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates, in particular, to methods for the diagnostic evaluation, genetic testing and prognosis of HKNG1 neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder.

The invention relates to a biological preparation for preventing and treating mental disorder based on photosynthetic bacteria. The preparation belongs to a probiotic agent capable of preventing and treating mental disorders such as depression and / or anxiety disorder, and has both preventive and therapeutic effects on the occurrence of mental disorders such as depression and / or anxiety disorder, and has no adverse reaction. The present invention has developed novel approaches to the prevention and treatment of mental disorders, such as depression and / or anxiety disorders.

The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.

Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (ω3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3 fatty acid may be administered orally, in amounts that may be variable, for example in amounts between 0.15 and 1.00 g / kg / day. The antidepressant may be any antidepressant, preferably the antidepressant is fluoxetine or mirtazapine in sub-optimal doses.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive- compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent.

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and / or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium / calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and / or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and / or premature ejaculation are described.

A method of treating a mental disorder including administering to a patient in need thereof, an effective amount of a pharmaceutical composition including 1,1-diphenyl-4-piperidine-1-ylbuthan-1-ol or a pharmaceutically acceptable salt thereof. The mental disorder is depression, bipolar disorder, anxiety disorder, impulsive disorder, bulimia, panic disorder, social anxiety disorder, insomnia, attention deficit hyperactivity disorder (ADHD), schizophrenia, dementia, personality disorder, alcoholism, dissociative disorder, sleep apnea syndrome, or fibromyalgia. In a preferred embodiment, the mental disorder as a therapeutic target is fibromyalgia, chronic fatigue syndrome (CFS), or depression with pain, and the administration of the pharmaceutical composition is capable of reducing the pain caused by these diseases.

The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Disclosed is the use of N-Methyl-D-aspartate (NMDA) antagonists at sub-anesthetic doses for the treatment of motor dysfunction in mental or psychiatric disorders with occurrence of aggressive and / or impulsive behavior.

The invention belongs to the field of compound drugs, and relates to new drug application of loganin, particularly application of loganin to the preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder. The loganin provided by the invention is one of main chemical components of Cornus officinalis which is a Cornaceae plant, the chemical formula of the loganin is C17H26O10, and the molecular weight of the loganin is 390.38; animal experiments prove that the loganin can reduce autonomous exercise intensity of a mouse, the number of rotational turns of a pulley poked by fore limbs of the mouse is obviously increased, the dead time of tail suspension of the mouse is shortened, and an antidepressant effect is shown; the loganin can further increase the time percentage of staying at the open arms of a maze of a stress rat and seek the frequency of arm opening, meanwhile, in a light and shade box shuttling experiment, the loganin can obviously increase the time that the mouse stays in a light box and the frequency of shuttling in the light box, and an obvious anxiolytic effect is shown. Above all, the loganin can be prepared into the drugs or health products for preventing and treating the mental disturbance diseases such as depressive disorder and anxiety disorder, and prepared dosage forms comprise granules, tablets, capsules, granules, powder, oral liquids, dropping pills, pellets or injections.